None listed
Conditions
Interventions
Intervention1: dry eye disease patient recieving standard treatment with omega 3 fatty acid: We will study effect of phacoemulsification on meibomian gland structure and function. we will examine pati
Sponsors
nil
Eligibility
Inclusion criteria
Inclusion criteria: Patients aged more than 40 years undergoing phacoemulsification cataract surgery at the Lens Clinic. A total of 100 prospective eyes from 100 patients will be included, all of whom will provide written informed consent to participate in the study. Only those who undergo cataract surgery by a single surgeon to reduce variability in surgical technique.
Exclusion criteria
Exclusion criteria: Patients with a history of previous ocular surgeries trauma uveitis glaucoma or active ocular infections. History of chronic ocular surface diseases (e.g., chalazion, pterygium, blepharitis, limbal stem cell deficiency, allergic eye diseases, or contact lens usage). Known pre-existing dry eye disease (e.g., OSDI more than 13 or TBUT less than 10). Patients who refuse participation after receiving information about the study and its objectives.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study the impact of phacoemulsification on meibomian gland structure and function, as assessed by non-contact meibography (LipiView II). Meibomian Gland Dysfunction (MGD) will be evaluated using meibography, which includes visualizing meibomian gland morphology and assessing gland dropout area. Lipid Layer Thickness (LLT) and Partial Blink Rate (PBR) will also be measured to evaluate meibomian gland function. Timepoint: Outcome will be assessed at 3rd weeks and 6th weeks post operative period to determine whether patient have develop dry eye post phacoemulsification | — |
Secondary
| Measure | Time frame |
|---|---|
| To study the impact of oral Omega-3 fatty acid therapy on post-phacoemulsification dry eye disease. o Patients will be randomised into two groups: one receiving Omega-3 fatty acid supplementation (1000mg/day, 650mg EPA + 350mg DHA in divided doses) in addition to standard dry eye management, & the other receiving SOC alone. o Both groups will be assessed for changes in OSDI, TBUT, Schirmer s test, & meibomian gland function (via meibography) after 6 weeks of start of treatment.Timepoint: Patient will be examine on 6th weeks post operative period to determine wheather patient have develop dry eye. If patient have develop dry eye he/she will be divided in 2 group , one group will receive standard of care & other group will receive standard of care along with omega 3 fatty acid for next 12 week. Then patient will be examine post 6 week start of treatment for improvement in dry eye on basis of OSDI, TBUT, schirmers test & meibography | — |
Countries
India
Contacts
Public ContactSumit Kumar Yadav
Post Graduate Institute of Medical Education and Research, Chandigarh
Outcome results
None listed